All Stories

  1. Agomelatine for depression: expanding the horizons?
  2. Problematic medical marijuana, but not all cannabinoids?
  3. One-Year Treatment Continuation in Patients Switched to Paliperidone Palmitate
  4. Impairments of Spatial Working Memory and Attention Following Acute Psychosocial Stress
  5. Agomelatine, melatonin and depressive disorder
  6. The effect of agomelatine on 5HT2C receptors in humans: a clinically relevant mechanism?
  7. The Decline and Fall of the Psychopharmacology Empire?
  8. Duloxetine in the acute and continuation treatment of major depressive disorder
  9. Contemporary Therapies for Depression in Older People
  10. Continuation treatment of major depressive disorder: is there a case for duloxetine?
  11. Dysfunctional Circadian Rhythms and Mood Disorders: Opportunities for Novel Therapeutic Approaches
  12. Melatonin: hormone of the night
  13. Abnormal dose-response melatonin suppression by light in bipolar type I patients compared with healthy adult subjects
  14. Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder
  15. Stability of cognitive impairment in chronic schizophrenia over brief and intermediate re-test intervals
  16. Duloxetine in the treatment of generalized anxiety disorder
  17. The Impact of a Changed Environment on Arousal Levels of Patients in a Secure Extended Rehabilitation Facility
  18. Quetiapine augmentation in depressed patients with partial response to antidepressants
  19. Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication
  20. How does your garden grow—therapeutic principles from herbal remedies?
  21. The neurobiology of benzodiazepine receptors in panic disorder and post‐traumatic stress disorder
  22. An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers
  23. Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression
  24. Behavioural studies of spatial working memory dysfunction in schizophrenia: A quantitative literature review
  25. Emerging treatments for major depression
  26. Neuropsychological study of underweight and “weight-recovered” anorexia nervosa compared with bulimia nervosa and normal controls
  27. An open-label study of quetiapine in anorexia nervosa
  28. Human Embryonic Stem Cells: A Resource for In Vitro Neuroscience Research?
  29. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins
  30. Prospects for the Treatment of Depression
  31. Prospects for the treatment of depression
  32. Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats
  33. Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists
  34. Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers
  35. Effect of Sodium Valproate on Nocturnal Melatonin Sensitivity to Light in Healthy Volunteers
  36. Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?
  37. Serotonergic and Dopaminergic Systems in Anorexia Nervosa: A Role for Atypical Antipsychotics?
  38. Fifth World Congress on Stress, London, 18–19 June 2004
  39. Prolactin response to d-fenfluramine in combat-related post-traumatic stress disorder
  40. An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat
  41. The emerging role of pharmacogenetics: implications for clinical psychiatry
  42. The Emerging Role of Pharmacogenetics: Implications for Clinical Psychiatry
  43. Mechanism of action of mirtazapine: dual action or dual effect?
  44. Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women
  45. Blunted growth hormone response to clonidine in post-traumatic stress disorder
  46. New Formulations of Existing Antidepressants
  47. The treatment of depression with different formulations of venlafaxine: a comparative analysis
  48. Blunted prolactin response to ?-fenfluramine in post-stroke major depression
  49. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers
  50. Brain monoamines and early visual information-processing speed
  51. Olanzapine excretion in human breast milk: estimation of infant exposure
  52. Guest Editorial: International Society for the Investigation of Stress (ISIS)
  53. Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers
  54. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes
  55. Book Review: Therapeutic Guidelines: Psychotropic, Version 4
  56. Mechanisms underlying the speed of onset of antidepressant response
  57. Third-Generation Antidepressants
  58. Nefazodone in the Breast Milk of Nursing Mothers: A Report of Two Patients
  59. Book Review: Differential Effects of Antidepressants
  60. Differential effects of antidepressants
  61. Antidepressants and Breast-Feeding
  62. Acute increases in night-time plasma melatonin levels following a period of meditation
  63. Pindolol Augmentation of Antidepressants: A Review and Rationale
  64. Stress induced animal models of depression
  65. The benzodiazepines: a brief review of pharmacology and therapeutics
  66. Sertraline in paired blood plasma and breast-milk samples from nursing mothers
  67. The Test Re-Test Reliability of the Melatonin Suppression by White Light
  68. Book Review: Drugs, the Brain and Behaviour: The Pharmacology of Abuse and Dependence
  69. The Evaluation of Depression in Inpatients with HIV Disease
  70. The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light
  71. The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light
  72. Book Review: Psychotropic Drug Handbook, 7th ed.
  73. Book Review: Handbook of Essential Psychopharmacology
  74. Book Review: Psychotropic Drug Handbook, 7th ed. Paul J. Perry, Bruce Alexander and Barry I. Liskow
  75. Effect of the menstrual cycle stage on the melatonin suppression by dim white light
  76. Melatonin sensitivity to dim white light in different seasons
  77. Melatonin sensitivity to dim white light in different seasons
  78. Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors
  79. Treatment of Anxiety During Pregnancy
  80. Plasma and human milk concentrations of moclobemide in nursing mothers
  81. Plasma and human milk concentrations of moclobemide in nursing mothers
  82. Subsensitive melatonin suppression by dim white light: possible biological marker of panic disorder
  83. Neurochemical effects of the enantiomers of mirtazapine in normal rats
  84. Evidence for 5-HT1A receptor control of pineal melatonin concentrations in the rat
  85. Modulation of plasma melatonin concentrations by changes in posture
  86. Platelet paroxetine binding in post-traumatic stress disorder
  87. Book Review: The Psychopharmacologists. Interviews by Dr David Healy. Altman, Chapman and Hall, London, 1996. No. of Pages: 633. Price £45.
  88. Book Review: The Psychopharmacologists. Interviews by Dr David Healy. Altman, Chapman and Hall, London, 1996. No. of Pages: 633. Price £45.
  89. ANTIDEPRESSANTS: CLINICAL ASPECTS
  90. Mood disturbance as a comorbid condition in schizophrenia: Etiology and treatment
  91. Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia
  92. Letter
  93. Platelet [3H]-paroxetine binding in obsessive-compulsive disorder
  94. Platelet [3H]paroxetine binding in panic disorder
  95. A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders
  96. Fast-Acting Antidepressants
  97. Differential Diagnosis and Drug Treatment of Panic Disorder, Anxiety and Depression
  98. Long-term management of depressive disorders
  99. Pharmacokinetic aspects of antidepressant treatment in the elderly
  100. A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness
  101. Prolactin response to dl-fenfluramine in panic disorder
  102. Plasma and breast milk concentrations of dothiepin and northiaden in lactating women
  103. Long-term drug treatment of panic disorder
  104. Alterations to Plasma Melatonin and Cortisol After Evening Alprazolam Administration in Humans
  105. Buspirone and Fluoxetine in the Treatment of OCD
  106. Stress and isatin: Effects on the serotonergic system
  107. Relationship of symptomatology of schizophrenia and tardive dyskinesia
  108. New Pharmacological Approaches to the Management of Depression: From Theory to Clinical Practice
  109. SEROTONERGIC FUNCTION IN PANIC DISORDER
  110. Fenfluramine Augmentation of Clomipramine Treatment of Obsessive Compulsive Disorder
  111. Breastfeeding and the use of psychotropic medication: a review
  112. High-affinity platelet [3H]LSD binding is decreased in panic disorder
  113. Pharmacokinetic and Pharmacodynamic Effects of a Single Nocturnal Dose of Alprazolam
  114. Pharmacotherapy of Panic Disorder
  115. Short-acting versus long-acting benzodiazepines: Discontinuation effects in panic disorders
  116. A Short Term Open Clinical Trial of Clobazam in the Treatment of Patients with Panic Attacks
  117. Platelet serotonin uptake in panic disorder patients: A replication study
  118. Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience
  119. Platelet serotonin response to treatment in geriatric depression
  120. Human Melatonin Suppression by Light is Intensity Dependent
  121. Antidepressant Drug Measurement: Review of Methods for Clinical Application
  122. The effect of stress on melatonin and serotonin in rat brain
  123. Human melatonin response to light at different times of the night
  124. Serotonin in Panic Disorder
  125. Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience
  126. Quantal melatonin suppression by exposure to low intensity light in man
  127. Relation Between Plasma Antidepressant Concentrations and Clinical Effects
  128. Platelet Serotonin Uptake in Panic Disorder: Comparison with Normal Controls and the Effect of Treatment
  129. A Case of Moclobemide Overdose
  130. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans
  131. Plasma Prolactin and Fluphenazine Concentrations in Patients receiving Fluphenazine Decanoate: Stability over Injection Intervals
  132. Platelet 3H-rauwolscine binding in patients with panic attacks
  133. PLATELET MONOAMINE OXIDASE ACTIVITY IN PATIENTS WITH HUNTINGTON'S DISEASE
  134. The pineal hormone melatonin in panic disorder
  135. Plasma immunoreactive β-endorphin in dexamethasone suppressors and non-suppressors of cortisol
  136. Melatonin Rhythm in Human Plasma Saliva
  137. Platelet monoamine uptake in depression — primary or secondary phenomenon?
  138. Platelet monoamine oxidase: Low activity in cigarette smokers
  139. Melatonin in panic disorder
  140. Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate)
  141. Plasma Melatonin Concentrations in Depression
  142. Platelet serotonin uptake in panic disorder
  143. Anxiety and the Benzodiazepine Receptor
  144. Pharmacological Treatment of Panic Disorder
  145. Determination of tiapride in plasma by high-performance liquid chromatography
  146. The biological basis of anxiety
  147. Analysis of tricyclic antidepressant drugs in plasma and serum by chromatographic techniques
  148. Antidepressant therapy: benefits and risks in perspective
  149. Plasma concentrations of benzodiazepines — A review of clinical findings and implications
  150. Maprotiline in affective illness
  151. The pharmacokinetics of mianserin in elderly depressed patients
  152. Zimelidine: A placebo-controlled trial in depression
  153. Monitoring and Interpretation of Antidepressant Plasma Concentrations
  154. Platelet monoamine oxidase activity and cigarette smoking
  155. Psychotherapeutic Drugs
  156. Viloxazine plasma concentrations and clinical response
  157. Determination of therapeutic levels of butriptyline in plasma by gas-liquid chromatography
  158. Iatrogenic psychosis
  159. Isotope Derivative Assays for Psychotropic Drugs
  160. Hypnosis in the Management of Stress and Anxiety Disorders
  161. Ethnic differences in psychotropic drug response and pharmacokinetics